Simple Hysterectomy Noninferior to Radical Hysterectomy with Respect to Pelvic Recurrence at 3 Years in Women with Low-Risk Cervical Cancer
Findings from the SHAPE study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
Safety and efficacy were evaluated in a global, multicentre, multicohort, open-label, single-arm study
At 3-Year Follow-Up Nivolumab Plus Chemotherapy Continued to Demonstrate OS Improvement in Patients with Advanced Gastro-Oesophageal Adenocarcinoma
Findings from the CheckMate 649 study
EMA Recommends Granting a Marketing Authorisation for Retifanlimab
It is indicated for the first-line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma
FDA Approves Osimertinib with Platinum-Based Chemotherapy for EGFR-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Evidence for efficacy is based on the results from the FLAURA 2 study
Activity and Safety of Regorafenib Plus Nivolumab in First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
Findings from the RENOBATE study
Longitudinal Profiling of the Gut Microbiome in Patients Undergoing Immune Checkpoint Blockade for Advanced Melanoma
Findings from a multicentre cohort study
FDA Approves Tepotinib for Metastatic Non-Small Cell Lung Cancer
Conversion to traditional approval is based on an additional patients and an added follow-up time to assess duration of response in the VISION study
Efficacy, Safety, and Translational Data from Durvalumab Plus Ceralasertib in Advanced/Metastatic NSCLC Following Prior Failure to Anti-PD1/PD-L1 and Platinum-Doublet Therapy
Findings from the HUDSON study
A Lack of Resistance Gene Alterations in Baseline ctDNA Associated with Prolonged OS After First-Line Treatment with Panitumumab plus Chemotherapy in Patients with RAS wt mCRC
Findings from an exploratory preplanned biomarker analysis of the PARADIGM study
FDA Approves Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
Evidence for efficacy is based on the results from the NAPOLI 3 study
An Increase in Healthcare Costs Associated with the Use of Multigene Panel Testing for the Treatment of Patients with Advanced Cancer
Findings from the OCTANE analysis